Introduction.
Airway mucus is a complex mixture of carbohydrates, mucin, proteins and
water. It is secreted by the submucosal glands and goblet cells of the airway mucosa to protect the lungs and humidify the air we breathe. However, factors like infection, oxidative stress and smoking can cause these glands to overproduce mucus. When combined with impaired ciliary function, this leads to mucus retention, difficulty expectorating sputum, and potentially severe breathing difficulties.
Expectorants are drugs that dilute sputum and reduce its viscosity, making it easier to cough up. Today, we will compare two classic expectorants widely used in clinical practice: N-acetylcysteine (NAC) and Ambroxol.
Part 1: Mechanisms of Action
Both drugs share several therapeutic effects, but their mechanisms differ slightly.
1. Expectorant Effect
· Ambroxol: It increases serous secretion, reduces sputum viscosity, promotes the release of pulmonary surfactant, and enhances ciliary motility to push sputum out.
· NAC: The sulfhydryl group in its molecular structure breaks the disulfide bonds between mucin complexes, reducing sputum viscosity and making it easier to cough up.
2. Antioxidant Effect
· Ambroxol: It activates the intracellular glutathione system, promoting glutathione synthesis to scavenge active peroxidation products and counteract free radical damage.
· NAC: It directly scavenges oxygen free radicals (like hydroxyl radicals and hydrogen peroxide). It also serves as a precursor for glutathione synthesis, maintaining sufficient glutathione levels to protect cells from damage.
3. Anti-inflammatory Effect
· Ambroxol: It resists free radicals and inhibits the release of inflammatory factors like histamine and leukotrienes, effectively suppressing the pro-inflammatory effects of leukocytes and macrophages.
· NAC: As an antioxidant, it inhibits oxidative stress-mediated inflammatory responses, alleviating lung tissue damage and inhibiting airway remodeling.
4. Antibacterial Effect
· Ambroxol: When combined with antibiotics (e.g., amoxicillin), it increases the concentration of these drugs in lung tissue, improving bacterial clearance and shortening antibiotic duration.
· NAC: It reduces the adhesion of bacteria (like Haemophilus influenzae and Streptococcus pneumoniae) to epithelial cells, inhibits bacterial colonization, and reduces viral replication.
5. Special Effects
· NAC: It serves as an antidote for acetaminophen poisoning and cyclophosphamide-induced hemorrhagic cystitis.
Part 2: Clinical Choices by Disease
Choosing between NAC and Ambroxol depends on the specific disease.
1. Chronic Obstructive Pulmonary Disease (COPD)
The GOLD guidelines suggest that for COPD patients not using inhaled corticosteroids (ICS), routine use of expectorants and antioxidants reduces acute exacerbations. Due to its strong expectorant, anti-inflammatory, and antioxidant effects, NAC is more suitable for COPD patients, as it alleviates oxidative stress and reduces exacerbation frequency.
2. Bronchiectasis
Patients with bronchiectasis often suffer from sputum accumulation and recurrent infections. Guidelines suggest long-term use (>3 months) of mucoactive drugs for patients with difficulty expectorating. Current research shows that combining bromhexine with antibiotics and nebulized NAC helps with sputum clearance. As the active metabolite of bromhexine, Ambroxol helps improve lung function and shorten hospitalization time for bronchiectasis patients with co-infections.
3. Idiopathic Interstitial Pneumonia (IPF)
IPF patients mainly present with dry cough and progressive dyspnea. Conventional expectorants seem to have little use here. However, as a glutathione precursor, NAC acts as an antioxidant. NAC monotherapy is effective for some IPF patients with the TOLLIP gene phenotype. Combining NAC with pirfenidone in intermediate-to-advanced IPF is superior to using pirfenidone alone.
4. Bronchial Asthma & ARDS
Currently, research evidence on using Ambroxol and NAC for bronchial asthma is limited. There is insufficient evidence to support that asthma patients benefit from expectorant treatment. Similarly, there is insufficient evidence to support the use of antioxidants like NAC for treating Acute Respiratory Distress Syndrome (ARDS).
Key Vocabulary :
· Expectorant: A medicine that helps bring up mucus from the airways (祛痰药).
· Viscosity: The state of being thick and sticky (黏稠度).
· Sulfhydryl group: A chemical group that helps break down mucus (巰基).
· Glutathione: A powerful antioxidant in the body (谷胱甘肽).
· Exacerbation: A worsening of a disease or its symptoms (急性加重).
· Ciliary motility: The movement of tiny hair-like structures in the airways (纖毛運動).
